| Joel Michael Stary, MD, PHD | |
|
1520 S Dobson Rd Ste 203, Mesa, AZ 85202-4726 | |
| (217) 721-3930 | |
| (480) 412-6999 |
| Full Name | Joel Michael Stary |
|---|---|
| Gender | Male |
| Speciality | Neurosurgery |
| Experience | 12 Years |
| Location | 1520 S Dobson Rd Ste 203, Mesa, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780945113 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Banner Desert Medical Center | Mesa, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Banner Physician Specialists Arizona Llc | 6204002272 | 258 |
News Archive
Other such pathways - known as surveillance pathways - operate in a more general way, in many cell types. Knowing how this specific surveillance system works can help researchers better understand hereditary diseases, in this case, thalassemia, a form of anemia, which is the most common genetic disorder worldwide.
Without proper infection prevention in hospitals, and now homes, the Clostridium difficile bacteria poses a major health threat, cautions a Case Western Reserve University infection control researcher.
Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.
Researchers at the Medical College of Wisconsin have identified novel biomarkers that could be used to confirm exposure to damaging radiation in large groups of people potentially exposed to unknown and variable doses for the purpose of triage and treatment.
This Malaria Policy Center blog post describes the event "Spurring health and wealth through medical breakthroughs," during which Washington Post columnist and ONE Fellow Michael Gerson; John Lusingu, principal research scientist at the Tanzania National Institute for Medical Research and co-principal investigator in the RTS,S malaria vaccine trial in Tanzania for the PATH Malaria Vaccine Initiative; and Margaret McGlynn, board member of the International AIDS Vaccine Initiative and former president of Merck Global Vaccines and Anti-Infectives, "brought unique perspectives to the impact of new vaccines on many global health issues, particularly HIV/AIDS and malaria".
› Verified 9 days ago
| Entity Name | Banner Physician Specialists Arizona Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316228802 PECOS PAC ID: 6204002272 Enrollment ID: O20111222000509 |
News Archive
Other such pathways - known as surveillance pathways - operate in a more general way, in many cell types. Knowing how this specific surveillance system works can help researchers better understand hereditary diseases, in this case, thalassemia, a form of anemia, which is the most common genetic disorder worldwide.
Without proper infection prevention in hospitals, and now homes, the Clostridium difficile bacteria poses a major health threat, cautions a Case Western Reserve University infection control researcher.
Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.
Researchers at the Medical College of Wisconsin have identified novel biomarkers that could be used to confirm exposure to damaging radiation in large groups of people potentially exposed to unknown and variable doses for the purpose of triage and treatment.
This Malaria Policy Center blog post describes the event "Spurring health and wealth through medical breakthroughs," during which Washington Post columnist and ONE Fellow Michael Gerson; John Lusingu, principal research scientist at the Tanzania National Institute for Medical Research and co-principal investigator in the RTS,S malaria vaccine trial in Tanzania for the PATH Malaria Vaccine Initiative; and Margaret McGlynn, board member of the International AIDS Vaccine Initiative and former president of Merck Global Vaccines and Anti-Infectives, "brought unique perspectives to the impact of new vaccines on many global health issues, particularly HIV/AIDS and malaria".
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joel Michael Stary, MD, PHD 1520 S Dobson Rd Ste 203, Mesa, AZ 85202-4726 Ph: (480) 412-8080 | Joel Michael Stary, MD, PHD 1520 S Dobson Rd Ste 203, Mesa, AZ 85202-4726 Ph: (217) 721-3930 |
News Archive
Other such pathways - known as surveillance pathways - operate in a more general way, in many cell types. Knowing how this specific surveillance system works can help researchers better understand hereditary diseases, in this case, thalassemia, a form of anemia, which is the most common genetic disorder worldwide.
Without proper infection prevention in hospitals, and now homes, the Clostridium difficile bacteria poses a major health threat, cautions a Case Western Reserve University infection control researcher.
Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.
Researchers at the Medical College of Wisconsin have identified novel biomarkers that could be used to confirm exposure to damaging radiation in large groups of people potentially exposed to unknown and variable doses for the purpose of triage and treatment.
This Malaria Policy Center blog post describes the event "Spurring health and wealth through medical breakthroughs," during which Washington Post columnist and ONE Fellow Michael Gerson; John Lusingu, principal research scientist at the Tanzania National Institute for Medical Research and co-principal investigator in the RTS,S malaria vaccine trial in Tanzania for the PATH Malaria Vaccine Initiative; and Margaret McGlynn, board member of the International AIDS Vaccine Initiative and former president of Merck Global Vaccines and Anti-Infectives, "brought unique perspectives to the impact of new vaccines on many global health issues, particularly HIV/AIDS and malaria".
› Verified 9 days ago
John I Iskandar, MD Neurological Surgery Medicare: Medicare Enrolled Practice Location: 2045 S Vineyard, 142, Mesa, AZ 85210 Phone: 480-330-6010 Fax: 480-507-0019 | |
Dr. Niteen S Andalkar, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 2045 S Vineyard, Ste. 142, Mesa, AZ 85210 Phone: 480-330-6010 Fax: 480-507-0019 | |
Dr. Mark Ercius, M.D. Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 1520 S. Dobson Rd, Suite 318, Mesa, AZ 85202 Phone: 480-833-5209 Fax: 480-835-5108 | |
Nikita George Alexiades, M.D. Neurological Surgery Medicare: Medicare Enrolled Practice Location: 1432 S Dobson Rd Ste 403, Mesa, AZ 85202 Phone: 480-412-7473 | |
Aimee Two, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 6832 E Brown Rd, Mesa, AZ 85207 Phone: 480-830-8333 Fax: 480-830-8390 |